For the quarter ending 2025-09-27, BVS made $138,652K in revenue. $3,155K in net income. Net profit margin of 2.28%.
| Income Statement | 2025-09-27 | 2025-06-28 | 2025-03-29 | 2024-09-28 |
|---|---|---|---|---|
| Income tax expense (benefit), net | 664 | 1,041 | -95 | 589 |
| Cost of sales (including depreciation and amortization of 9,995, 10,206, 30,863 and 31,252, respectively) | 44,422 | 45,570 | 40,820 | 45,413 |
| Net sales | 138,651 | 147,660 | 123,876 | 138,964 |
| Gross profit | 94,229 | 102,090 | 83,056 | 93,551 |
| Selling, general and administrative expense | 78,657 | 79,110 | 73,502 | 81,090 |
| Research and development expense | 2,923 | 3,172 | 3,011 | 3,808 |
| Change in fair value of contingent consideration | 0 | 0 | - | 483 |
| Depreciation and amortization | 1,398 | 1,439 | 1,593 | 2,065 |
| Impairment of assets | 0 | 0 | - | 2,031 |
| (gain) loss on disposals | 1 | -1 | -81 | - |
| Operating income (loss) | 11,252 | 18,368 | 4,869 | 4,074 |
| Interest expense, net | -6,177 | -7,494 | -7,509 | -9,532 |
| Loss on extinguishment | -326 | - | - | - |
| Other expense (income), net | -79 | -561 | -777 | 626 |
| Other expense | -6,582 | -8,055 | -8,286 | -8,906 |
| Net loss from continuing operations | - | - | - | -5,421 |
| Income (loss) before income taxes | 4,670 | 10,313 | -3,417 | -4,832 |
| Net income (loss) | 4,006 | 9,272 | -3,322 | -5,421 |
| Loss attributable to noncontrolling interest - continuing operations | - | - | - | -597 |
| (income) loss attributable to noncontrolling interest | 851 | 1,813 | -685 | - |
| Net income (loss) attributable to bioventus inc | 3,155 | 7,459 | -2,637 | -4,824 |
| Basic (in shares) | 66,924,682 | 66,500,433 | 66,008,683 | 65,258,427 |
| Diluted (in shares) | 68,837,797 | 68,536,759 | 66,008,683 | 65,258,427 |
| Loss per share of class a common stock, basic (in dollars per share) | 0.05 | 0.11 | -0.04 | -0.07 |
| Loss per share of class a common stock, diluted (in dollars per share) | 0.05 | 0.11 | -0.04 | -0.07 |
Bioventus Inc. (BVS)
Bioventus Inc. (BVS)